NCT05253066尚未招募2 期
An Open, Multicenter, Randomized Controlled Clinical Study of Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 130
- 主要终点
- ORR
研究概览
简要总结
This is an open, multicenter, randomized controlled clinical study aimed to explore the efficacy and safety of chidamide combined with exemestane (+/- goserelin) versus chemotherapy in the neoadjuvant treatment of stage II-III HR +/HER2- breast cancer patients with poor response to previous chemotherapy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •female patients aged greater than or equal to 18 years and less than or equal to 75 years, meet one of the following:
- •previous oophorectomy, or age ≥ 60 years;
- •age < 60 years, natural postmenopausal status (defined as at least 12 consecutive months of spontaneous cessation of regular menstruation, and no other pathological or physiological causes), E2 and FSH in postmenopausal levels;
- •premenopausal or perimenopausal female patients, must be willing to receive LHRH agonist therapy during the study;
- •all patients were confirmed by histopathology as estrogen receptor (ER) positive (> 10%), HER2 receptor negative.Follow the 2018 version of ASCO-CAP HER2-negative interpretation guideline criteria;
- •tumor stage II-III meeting the AJCC 8th version criteria, patients who have previously received 2 cycles of TE regimen chemotherapy, with disease evaluation of SD or PD;
- •KPS score ≥ 70 points;
- •organ function level must meet the following requirements:
- •bone marrow function ANC ≥ 1.5 × 109/L (14 without growth factors); PLT ≥ 100 × 109/L (7 without corrective treatment); Hb ≥ 100 g/L (7) without corrective treatment;
- •liver and kidney function TBIL ≤ 1.5 × ULN; ALT and AST ≤ 3 × ULN; BUN and Cr ≤ 1.5 × ULN and creatinine clearance ≥ 50 mL/min (Cockcroft-Gault formula);
- •able to undergo needle biopsy;
- •voluntarily join this study, sign informed consent, have good compliance and are willing to cooperate with follow-up
排除标准
- •received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.);
- •received any other anti-tumor therapy at the same time;
- •breast cancer, inflammatory breast cancer or occult breast cancer;
- •stage IV breast cancer;
- •breast cancer without histopathological diagnosis;
研究组 & 干预措施
Chidamide group
Experimental
Chidamide combined with exemestane (+/- goserelin)
干预措施: Chidamide combined with exemestane (+/- goserelin) (Drug)
chemotherapy group
Active Comparator
Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician)
干预措施: Chemotherapy with docetaxel plus epirubicin or change of chemotherapy regimen (at the discretion of the clinician) (Drug)
结局指标
主要结局
ORR
时间窗: Up to approximately 48 months
次要结局
- patient-reported outcome（PRO）：evaluate daily functioning and health outcomes from the patient's perspective by HRQOL(Up to approximately 48 months)
- pCR：Upon completion of neoadjuvant therapy and surgery, there was no residual invasive carcinoma present in the pathologic assessment of the resected breast cancer samples stained with hematoxylin and eosin and all ipsilateral lymph node samples.(Up to approximately 48 months)
- Breast-conserving rate(Up to approximately 48 months)
- Number of participants with treatment-related adverse events as assessed by CTCAE v5.0(Up to approximately 48 months)
- Total breast pathological complete remission rate (bpCR)(Up to approximately 48 months)
- PEPI classification(Up to approximately 48 months)
- Number of participants with treatment-related serious adverse event as assessed by CTCAE v5.0(Up to approximately 48 months)
- Residual tumor burden (RCB) classification(Up to approximately 48 months)
研究者
相似试验
已完成
2 期
Efficacy and Safety of Combination Therapy With Bojungikki-tang and Pembrolizumab Monotherapy in Patients With Advanced Non-small Cell Lung CancerNon-small Cell Lung CancerNCT06249854Korea Institute of Oriental Medicine26
Unknown
不适用
Efficacy and Safety of PEG-rhG-CSF in the Prevention of Neutropenia After Chemo in Pts With Gynecological MalignanciesGynecologic Malignant TumorNCT04773327Xiaohua Wu MD150
尚未招募
4 期
Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral MetastasisBreast Cancer Stage IVNCT05860907Fudan University384
Unknown
不适用
Effectiveness and Safety of Rhea Health Tone® as add-on Therapy for COVID-19 in Hospitalized Adults in IndonesiaCovid19NCT04627519Universitas Padjadjaran85
招募中
3 期
Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentMantle Cell Lymphoma (MCL)NCT06496308Ruijin Hospital78